Immune System News and Research

RSS

Stem cells - the answer to autoimmune diseases and cancer in the future

Stem cells are multipotent cells of the immune system. Scientists hope to use them for curing autoimmune diseases, cancer and innate genetic defects in the future.

16 Sep 2009

Patients with celiac disease face increased risk of mortality

New research indicates that patients with lesser degrees of celiac disease-related symptoms, such as intestinal inflammation or latent celiac disease, have a modestly increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

New cancer therapy involves remodelling blood vessels and activating immune cells

Reversing or re-arranging the growth of these vessels in combination with specific immune strategies is a promising new strategy for cancer therapy, says Ruth Ganss, Professor at the Western Australian Institute for Medical Research, Perth, at the 2nd European Congress of Immunology ECI 2009 held in Berlin.

16 Sep 2009

BioMedReports.Com issues special investigative report on CEL-SCI

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation.

16 Sep 2009

HemoRANK-TKI in vitro assay service package from ReachBio

ReachBio LLC announced today the launch of HemoRANK(TM)-TKI, an in vitro assay service package that helps predict the potential of novel therapeutic tyrosine kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia).

16 Sep 2009

Ganeden Biotech unveils the first quick dissolving, thin strip probiotic product

Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30(R), today announced the launch of the first quick dissolving, thin strip probiotic product. The new thin strip product is the latest in a number of innovative probiotic-enhanced products introduced by Ganeden Biotech over the past year.

16 Sep 2009

PsoriasisDX Genetic Test for Psoriatic arthritis launched

The first genetic test for Psoriatic arthritis (PsA) is being launched today by PsoriasisDX, LLC, a subsidiary of molecular dermatology research and development innovator PharmaGenoma, Inc. PsA is a progressive irreversible joint disease associated with psoriasis. It is estimated that 20% to 40% of psoriasis patients will eventually develop PsA.

16 Sep 2009

NCI-funded SPORE grant aims to improve kidney cancer treatment

The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney. Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.

16 Sep 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

New data reveals the evolution of Immunoglobulin E

Immunoglobulin E (IgE) is the main actor in the drama of allergy. The biological role of IgE in the immune response of an organism and the lack of control leading to allergy is the research topic of Gernot Achatz, Molekular Biology, University of Salzburg. At the 2nd European Congress of Immunology ECI 2009 held in Berlin the scientist presents new data revealing the evolution of IgE.

15 Sep 2009

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

Merck Sharp & Dohme Limited (MSD) announced today that ISENTRESS® (raltegravir) has been granted an expanded licence from the European Union Commission (Commission) for use in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infection in adult patients, including adult patients starting HIV-1 therapy for the first time (treatment-naïve), as well as treatment-experienced adult patients.

15 Sep 2009

Phase III results of Lauriad presented at the 49th Annual ICAAC

BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad and anti-integrase inhibitor.

15 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

15 Sep 2009

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University Medical Center has received a $2 million matching grant from The Coleman Foundation to renovate the hospital's nationally known bone marrow transplant unit. Intended to encourage private donations for the project, the grant will match gifts up to $2 million on a dollar for dollar basis, through August 2010.

15 Sep 2009

Prebiotic Inulin fiber supplement from Standard Process

Our gut is home to different types of bacteria, many of which live in harmony with us. Maintaining a balance of helpful bacteria within the gut is important for the health of several body functions. To help provide a favorable environment for friendly microbes to thrive, Standard Process Inc.® proudly introduces its newest product, Prebiotic Inulin.

15 Sep 2009

Study reveals that daily bathroom showers may deliver pathogenic bacteria

While daily bathroom showers provide invigorating relief and a good cleansing for millions of Americans, they also can deliver a face full of potentially pathogenic bacteria, according to a surprising new University of Colorado at Boulder study.

15 Sep 2009

Report on the epidemiology, cause and risk factors of asthma

An article on the epidemiology, cause and risk factors of asthma is the first in a special report on asthma in CMAJ (Canadian Medical Association Journal) designed for clinical practitioners. This review looks at risk factors for persistent asthma at different ages, including prenatal, infancy, childhood and adulthood.

15 Sep 2009